ଫୁସଫୁସ କ୍ୟାନ୍ସର (ନନ୍-ସ୍ମଲ୍ ସେଲ୍)
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ 13 ଟି hospital ଭାରତରେ ରୋଗୀ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
ସ୍ପୋନ୍ସର: ମିରାଟି ଥେରାପ୍ୟୁଟିକ୍ସ ଇନ୍କ.
ClinicalTrials.gov ରେ NCT04613596
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 13 ଅକ୍ଟୋବର 2026 · ଆମେ ପଢିଲୁ 20 ଅକ୍ଟୋବର 2026